Julia von Tresckow, MD^1*, Paula Cramer, MD^2*, Jasmin Bahlo^3*, Anja Engelke, MD^1*, Petra Langerbeins, MD^2*, Anna-Maria Fink, MD^2*, Holger Klaproth, MD^4*, Eugen Tausch, MD^5*, Kirsten Fischer, MD^2*, Clemens-Martin Wendtner, MD^1,6, Karl-Anton Kreuzer^2*, Stephan Stilgenbauer, MD⁷, Sebastian Boettcher, MD^8*, Barbara Eichhorst, MD³ and Michael Hallek, MD⁹

¹Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany
²Department I of Internal Medicine, University of Cologne, Cologne, Germany
³Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany
⁴Hämatologische/ Onkologische Praxis Dr. Schmidt/Klaproth, Neunkirchen, Germany
⁵Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany
⁶Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Hospital Munich-Schwabing, Munich, Germany
⁷Department of Internal Medicine III, Ulm University, Ulm, Germany
⁸Second Department of Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany
⁹Department of Internal Medicine, University of Cologne, Cologne, Germany

Jeff P. Sharman, MD¹, Leonard M. Klein, MD², Michael Boxer, MD³, Kathryn S. Kolibaba, MD⁴, Steve Abella, MD^5*, Julie Di Paolo, PhD^5*, Clarence Eng, MPH^5*, Jing Hu, PhD^5*, Jing He^6*, Anita Reddy, PhD^6* and Christopher A. Yasenchak, MD⁷

¹Willamette Valley Cancer Institute, Springfield, OR
²Illinois Cancer Specialists, Niles, IL
³Arizona Oncology Associates, Tucson, AZ
⁴Compass Oncology/US Oncology Research, Vancouver, WA
⁵Gilead Sciences, Inc., Foster City, CA
⁶Gilead Sciences, Inc, Foster City, CA
⁷Willamette Valley Cancer Institute and Research Center/US Oncology Research, Springfield, OR

Susan O'Brien, MD¹, Samantha Jaglowski, MD, MPH^2*, John C. Byrd, MD², Rajat Bannerji, MD, PhD³, Kristie Blum, MD⁴, Christopher P. Fox, MBChB, PhD^5*, Richard R. Furman, MD⁶, Peter Hillmen⁷, Thomas J. Kipps, MD⁸, Marco Montillo, MD⁹, Jeff Sharman, MD^10*, Sam Suzuki, MS, MBA^11*, Danelle James, MD, MAS^11*, Alvina D. Chu, MD^11* and Steven Coutre, MD^12*

¹MD Anderson Cancer Center, Houston, TX
²The Ohio State University Medical Center, Columbus, OH
³Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
⁴Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
⁵Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
⁶Weill Cornell Medical College, New York, NY
⁷Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom
⁸Moores UCSC Cancer Center, San Diego, CA
⁹Niguarda Ca’ Granda Hospital, Milan, Italy
¹⁰Willamette Valley Cancer Institute, Eugene, OR
¹¹Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹²Stanford University School of Medicine, Stanford, CA

Owen A. O'Connor, MD¹, Ian W. Flinn, MD, PhD^2,3, Manish R. Patel, MD^2,4, Timothy S. Fenske, MD⁵, Changchun Deng, MD, PhD¹, Danielle M. Brander, MD⁶, Martin Gutierrez, MD^7*, Suzanne Jones, PharmD², John G Kuhn, Pharm.D.^8*, Hari P. Miskin, MS^9*, Peter Sportelli⁹, Swaroop Vakkalanka, PhD^10* and Howard A. Burris III, MD^2,3

¹Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY
²Sarah Cannon Research Institute, Nashville, TN
³Tennessee Oncology, PLLC, Nashville, TN
⁴Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL
⁵Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI
⁶Duke University Medical Center, Durham, NC
⁷John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
⁸University of Texas Health Science Center at San Antonio, San Antonio, TX
⁹TG Therapeutics, Inc., New York, NY
¹⁰Rhizen Pharmaceuticals SA, La Chaux-de-Fonds, Switzerland

Jacqueline C. Barrientos, MD¹, Manmeen Kaur, MD^2*, Alexis Mark^2*, Jaewon Chung^2*, Nancy Driscoll, PA-C^3*, Alison Bender, PA-C^4* and Kanti R. Rai, MD⁵

¹Department of Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY
²Hofstra North Shore-LIJ School of Medicine, Hempstead, NY
³Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY
⁴Department of Medicine, Division of Hematology-Oncology, Hofstra North-Shore LIJ School of Medicine, Hempstead, NY
⁵The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY

Gabor Kovacs, MD^1*, Jasmin Bahlo^1*, Sandra Kluth^1*, Paula Cramer, MD^1*, Anna-Maria Fink, MD^1*, Kirsten Fischer, MD^1*, Carolin Gross-Ophoff-Mueller, MD^1*, Petra Langerbeins, MD^1*, Christian Maurer, MD^1*, Julia von Tresckow, MD^1*, Clemens-Martin Wendtner, MD^1,2, Stephan Stilgenbauer, MD³, Michael Hallek, MD¹, Barbara Eichhorst, MD¹ and Valentin Goede, MD^1,4*

¹Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Cologne, Germany
²Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Hospital Munich-Schwabing, Munich, Germany
³Department III of Internal Medicine, University of Ulm, Ulm, Germany
⁴German CLL Study Group, Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany

Loïc Ysebaert, MD, PhD^1,2*, Christian Klein, PhD³ and Anne Quillet-Mary, PhD^2*

¹University Hospital of Toulouse, Hematology, Toulouse, France
²Cancer Research Center of Toulouse, INSERM U1037/CNRS ERL5294/UPS, Toulouse, France
³Roche Innovation Center Zurich, Schlieren, Switzerland

Matthew S. Davids, MD¹, Haesook T. Kim, PhD^2*, Elizabeth Gilbert^3*, Leslie Cowen^3*, Karen Francoeur, RN^4*, Jeffrey Hellman, PA-C^4*, Jon E. Arnason, MD⁵, David C. Fisher, MD⁶ and Jennifer R. Brown, MD, PhD³

¹Dana-Farber Cancer Institute, Boston, MA
²Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
³Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
⁶Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Matthew S. Davids, MD¹, Haesook T. Kim, PhD^2*, Stacey M. Fernandes^3*, Jeffrey Hellman, PA-C^3*, Karen Francoeur, RN^3*, Jon E. Arnason, MD⁴, Eric Jacobsen, MD³, Ann S LaCasce, MD³, David C. Fisher, MD⁵ and Jennifer R. Brown, MD, PhD⁶

¹Dana-Farber Cancer Institute, Boston, MA
²Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
⁵Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Januario E. Castro, M.D.¹, Michael Y. Choi, M.D.², Carlos I. Amaya-Chanaga, M.D.^2*, Natalie Nguyen, B.Sc^2*, Amine Ale-Ali, PharmD^2* and Thomas J. Kipps, M.D., PhD.¹

¹Moores UCSD Cancer Center, CLL Research Consortium, University of California, San Diego, La Jolla, CA
²Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA

Robert J. Kreitman, MD¹, Evgeny Arons, PhD¹, Martin S Tallman, MD^2*, Robak Tadeusz, MD, PhD^3*, Steven Coutre, MD^4*, Wyndham H Wilson, MD, PhD⁵, Maryalice Stetler-Stevenson, MD, PhD⁶, Constance M. Yuan, MD, PhD^6*, Mark Lanasa, MD, PhD⁷, David JP FitzGerald, PhD^1* and Ira Pastan, MD^1*

¹Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD
²Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
³Department of Hematology, Medical University of Lodz, Lodz, Poland
⁴Stanford Cancer Center, Stanford University, Stanford, CA
⁵Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD
⁶Laboratory of Pathology, National Cancer Institute, Bethesda, MD
⁷Clinical Development, Oncology, MedImmune, Gaithersburg, MD

Manoj K. Kashyap, PhD^1*, Carlos I. Amaya-Chanaga, M.D.^1*, Deepak Kumar, PhD¹, Michael Y. Choi, M.D.², Laura Z. Rassenti, PhD³, Amine Ale-Ali, PharmD^1*, Shu-Hui Liu, PhD^4*, Tod Smeal^5*, Valeria Fantin, PhD^5*, Thomas J. Kipps, M.D., PhD.¹, Flavia Pernasetti^5* and Januario E. Castro, MD³

¹Moores Cancer Center, University of California, San Diego, La Jolla, CA
²University of California, San Diego, La Jolla, CA
³Moores UCSD Cancer Center, CLL Research Consortium, La Jolla, CA
⁴Rinat, Pfizer, South San Francisco, CA
⁵Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, CA

Christine I Chen, MD¹, Harminder Paul^1*, Susi Snitzler, RN^1*, Lisa W Le, MSc^2*, Ellen Nong Wei^1*, Anthea Lau^2*, James B Johnston, MD³, Spencer B. Gibson, PhD^4*, Michelle L. Queau, B.Sc^4* and Suzanne Trudel, MD¹

¹Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
²Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada
³Manitoba Institute of Cell Biology, Cancer Care Manitoba, Winnipeg, MB, Canada
⁴Research Institute of Oncology and Hematology, Cancer Care Manitoba, Winnipeg, MB, Canada

Maria Winqvist, MD^1*, Fariba Mozaffari, PhD^2*, Marzia Palma, MD, PhD^1*, Sandra Eketorp Sylvan, MD, PhD^1*, Hakan Mellstedt, MD, PhD^2*, Anders Osterborg, MD, PhD¹ and Jeanette Lundin, MD, PhD^3*

¹Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden
²Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
³Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

Nisar A. Amin^1*, Sriram Balasubramanian, PhD², Kamlai Saiya-Cork^1* and Sami N. Malek³

¹University of Michigan, Ann Arbor, MI
²Janssen Research & Development, Springhouse, PA
³Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI

Anna Asklid, MD^1*, Agnes Mattsson, MD^2*, Einar Björgvinsson, MD^1*, Maria Winqvist, MD^3*, Sandra Eketorp Sylvan, MD, PhD^3*, Frans Søltoft, MSc^4*, Johanna Repits, PhD^5*, Joris Diels^6*, Anders Österborg, MD, PhD³ and Lotta Hansson, MD, PhD^3*

¹Department of Oncology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
²Department of Internal Medicine, Södersjukhuset and Karolinska Institutet, Stockholm, Sweden
³Department of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
⁴Nordic Health Economic Manager, Janssen Cilag, Stockholm, Sweden
⁵Nordics team, Janssen Cilag, Stockholm, Sweden
⁶Janssen EU HEMAR Statistics & Modeling, Beerse, Belgium

Joshua M. Allen, MD^1*, Lisa A. Rybicki, MS^2*, Paolo F. Caimi, MD³, Deepa Jagadeesh, MD, MPH⁴, Robert M. Dean, MD⁵, Brad Pohlman, MD⁶, Mitchell R. Smith, MD, PhD⁵, Matt Kalaycio, MD⁷ and Brian T. Hill, MD, PhD⁵

¹Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
²Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH
³Medicine - Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
⁴Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
⁵Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁶Blood and Marrow Transplant, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁷Leukemia Program, Cleveland Clinic, Cleveland, OH

Charlotte Schmidt-Salzmann, MD^1*, Niuscha Yaktapour, PhD^1*, Tilman Brummer, PhD^2*, Katja Zirlik, MD¹ and Rainer Claus, MD^1*

¹Div. Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg, Germany
²BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany

Mazie Tsang, MD^1*, Kari Rabe Chaffee, MS^2*, Timothy G. Call, MD³, Wei Ding, MD, PhD¹, Jose F. Leis, MD, PhD⁴, Asher Chanan-Khan, MD⁵, Michael Conte, PA-C^3*, Deborah A. Bowen, APRN, CNP^3*, Susan M. Schwager^1*, Susan L. Slager, PhD⁶, Neil E. Kay, MD³, Tait D. Shanafelt, M.D.⁷ and Sameer A. Parikh, MD³

¹Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
²Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN
³Division of Hematology, Mayo Clinic, Rochester, MN
⁴Department of Hematology, Mayo Clinic, Scottsdale, AZ
⁵Division of Hematology, Mayo Clinic, Jacksonville, FL
⁶Department of Health Sciences Research, Mayo Clinic, Rochester, MN
⁷Hematology, Mayo Clinic, Rochester, MN

Godelieve Meunier^1*, Loïc Ysebaert, MD, PhD^2*, Phi Linh Nguyen-Thi, MD, PhD^3*, Stephane Lepretre, MD^4*, Anne Quinquenel, MD^5*, Jehan Dupuis, MD^6*, Richard Lemal, MD^7*, Therese Aurran-Schleinitz, MD^8*, Cecile Tomowiak, MD^9*, Florence Cymbalista, MD, PhD¹⁰, Marie Sarah Dilhuydy, MD^11*, Annie Brion, MD^12*, Pierre Morel, MD¹³, Bruno Cazin, MD^14*, Veronique Leblond, MD¹⁵, Guillaume Cartron, MD, PhD^16*, Daniel Ré, MD^17*, Marie C Bene, PharmSciD, PhD^18*, Anne-Sophie Michallet, MD^19* and Pierre Feugier, MD, PhD^20*

¹Service d'Hématologie, Hôpital Brabois, Vandoeuvre Les Nancy, France
²University Hospital of Toulouse, Hematology, Toulouse, France
³CHU Nancy, Nancy, France
⁴Hematology, CLCC H Becquerel, Rouen, France
⁵Hopital Robert Debre, Reims, France
⁶Lymphoid Malignancies Unit, APHP, Groupe Hospitalier Mondor, CRETEIL, France
⁷CHU Clermont Ferrand, Clermont Ferrand, France
⁸Hematology Department, Institut Paoli Calmettes, Marseille, France
⁹CHU, Poitiers, France
¹⁰Hematology Biology, Hopital Avicenne, AP-HP, Bobigny, France
¹¹Hôpital Haut-Lévêque, Pessac, France
¹²Hopital Jean Minjoz, Besancon, France
¹³Service d'Hematologie, CH Lens, Lens, France
¹⁴Maladies du Sang, Hôpital Claude Huriez, CHRU Lille, Lille, France
¹⁵Department of Clinical Hematology, Pitie-Salpetriere Hospital and Pierre et Marie Curie University, Paris, France
¹⁶Department of Clinical Hematology, University Hospital of Montpellier, Montpellier, France
¹⁷CH Antibes, Antibes, France
¹⁸Hematology Laboratory, Nantes University Hospital, Nantes, France
¹⁹CHU Lyon Sud-Pierre Bénite, Pierre-Benite, France
²⁰CHU et INSERM 954, Nancy Université, Vandoeuvre Les Nancy, France

Paolo Ghia, MD, PhD¹, Lydia Scarfo^2*, Kumudu Pathiraja^3*, Martha Derosier^3*, Karen Small^3* and Nigel Patton^4*

¹Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milano, Italy
²Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy
³Merck & Co., Inc., Kenilworth, NJ
⁴Auckland City Hospital, Auckland, New Zealand

Shringi Sharma, PhD^1*, Ying Guo, PhD^1*, Feng Jin, PhD^1*, Xiaoming Li, PhD^1*, Ronald L. Dubowy, MD¹, Terry Newcomb, PhD^2* and Srini Ramanathan, PhD^1*

¹Gilead Sciences, Foster City, CA
²Gilead Sciences, Inc., Foster City, CA